Showing results (181-190 of 216) with videos related to

Sort By:
Pageof 22
Nature|March 28, 2014
Metabolic determinants of cancer cell sensitivity to glucose limitation and biguanidesKıvanç Birsoy, Richard Possemato, Franziska K Lorbeer, et al.
Clinical Laboratory|December 23, 2008
Serum zinc and copper status in dyslipidaemic patients with and without established coronary artery diseaseMajid Ghayour-Mobarhan, Andrew Taylor, Seyyed Mohammad Reza Kazemi-Bajestani, et al.
Canadian Journal of Ophthalmology. Journal Canadien D'Ophtalmologie|May 29, 2024
The Fight Tumour Blindness Registry: Efficient capture of high-quality real-world data in uveal melanomaRoderick F O'Day, R Max Conway, Li-Anne Lim, et al.
Cell|February 2, 2024
Brain-wide neural activity underlying memory-guided movementSusu Chen, Yi Liu, Ziyue Aiden Wang, et al.
Cell|March 15, 2016
The CASTOR Proteins Are Arginine Sensors for the mTORC1 PathwayLynne Chantranupong, Sonia M Scaria, Robert A Saxton, et al.
Brain Communications|July 31, 2025
Depicting multiple sclerosis disease course using lesion parenchymal fraction: a quantified expression of the topographical model of multiple sclerosisStephen Krieger, Thibo Billiet, Nuno Pedrosa de Barros, et al.
Plos One|March 5, 2015
Reciprocal interaction of Wnt and RXR-α pathways in hepatocyte development and hepatocellular carcinomaJinyu Li, Maia Chanrion, Eric Sawey, et al.
Scientific Reports|December 11, 2023
Protein and lipid expansion microscopy with trypsin and tyramide signal amplification for 3D imagingUeh-Ting Tim Wang, Xuejiao Tian, Yae-Huei Liou, et al.
European Journal of Cancer (Oxford, England : 1990)|November 16, 2018
Rheumatic immune-related adverse events secondary to anti-programmed death-1 antibodies and preliminary analysis on the impact of corticosteroids on anti-tumour response: A case seriesEmma L Mitchell, Peter Kar Han Lau, Chloe Khoo, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|June 19, 2018
Successful implementation of an automated electronic support system for patient safety monitoring: The alemtuzumab in multiple sclerosis safety systems (AMS3) studyStephen W Reddel, Michael H Barnett, Sean Riminton, et al.
Pageof 22